(22UA) BioNTech SE - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Common Stock • ISIN: US09075V1026
22UA: Cancer, Vaccines, Immunotherapies, Antibodies, Small Molecules
BioNTech SE, a trailblazer in the biotechnology sector, specializes in mRNA-based immunotherapies, renowned for their innovative approach to treating cancers and infectious diseases. Their collaboration with pharmaceutical giants like Pfizer underscores their strategic prowess and commitment to advancing medical science.
Their FixVac product line is a testament to their dedication, with BNT111 in Phase II trials for advanced melanoma, BNT112 targeting prostate cancer, and BNT113 addressing HPV-related head and neck cancers. BNT114 focuses on triple-negative breast cancer, while BNT115 and BNT116 are in early stages for ovarian and non-small cell lung cancers, respectively.
Beyond FixVac, BioNTechs pipeline includes BNT122 for melanoma and solid tumors, BNT131 for multiple solid tumors, and several other candidates in various stages of development. Their prophylactic vaccine efforts target shingles, malaria, and HSV-2, showcasing a broad preventive approach.
Financially, BioNTech stands strong with a market cap of 24,765.14M EUR and a forward P/E of 7.14. Their partnerships with Genentech, Sanofi, and CEPI highlight their collaborative spirit and strategic focus on mRNA technology, positioning them as a key player in the biotech industry.
Investors and fund managers will note their robust pipeline, strategic alliances, and financial stability, making BioNTech a compelling consideration in the biotechnology sector.
Additional Sources for 22UA Stock
22UA Stock Overview
| Market Cap in USD | 22,784m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception |
22UA Stock Ratings
| Growth 5y | 3.59% |
| Fundamental | -21.4% |
| Dividend | 1.0% |
| Rel. Strength | 15.4 |
| Analysts | - |
| Fair Price Momentum | 77.22 EUR |
| Fair Price DCF | - |
22UA Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | % |
| Annual Growth 5y | -100.00% |
| Payout Consistency | 1.7% |
22UA Growth Ratios
| Growth Correlation 3m | -79.6% |
| Growth Correlation 12m | 66.4% |
| Growth Correlation 5y | -46.3% |
| CAGR 5y | 2.38% |
| CAGR/Max DD 5y | 0.03 |
| Sharpe Ratio 12m | -1.11 |
| Alpha | -2.86 |
| Beta | 0.308 |
| Volatility | 41.21% |
| Current Volume | 29.8k |
| Average Volume 20d | 36.6k |
As of April 02, 2025, the stock is trading at EUR 84.90 with a total of 29,819 shares traded.
Over the past week, the price has changed by -6.70%, over one month by -21.10%, over three months by -24.73% and over the past year by -0.35%.
Neither. Based on ValueRay Fundamental Analyses, BioNTech SE is currently (April 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -21.39 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of 22UA as of April 2025 is 77.22. This means that 22UA is currently overvalued and has a potential downside of -9.05%.
BioNTech SE has no consensus analysts rating.
According to ValueRays Forecast Model, 22UA BioNTech SE will be worth about 84.2 in April 2026. The stock is currently trading at 84.90. This means that the stock has a potential downside of -0.84%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 84.2 | -0.8% |